TY - JOUR AU - Bray, F. AU - Ren, J. S. AU - Masuyer, E. AU - Ferlay, J. PY - 2013 DA - 2013// TI - Global estimates of cancer prevalence for 27 sites in the adult population in 2008 JO - International journal of cancer Journal international du cancer VL - 132 UR - https://doi.org/10.1002/ijc.27711 DO - 10.1002/ijc.27711 ID - Bray2013 ER - TY - STD TI - Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], Available from: http://globocan.iarc.fr. In Book GLOBOCAN 2008 v2.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], Available from: http://globocan.iarc.fr (Editor ed.^eds.). City: International Agency for Research on Cancer; 2010. ID - ref2 ER - TY - JOUR AU - Cardoso, F. AU - Harbeck, N. AU - Fallowfield, L. AU - Kyriakides, S. AU - Senkus, E. PY - 2012 DA - 2012// TI - Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Annals of Oncology VL - 23 UR - https://doi.org/10.1093/annonc/mds232 DO - 10.1093/annonc/mds232 ID - Cardoso2012 ER - TY - JOUR AU - Kennecke, H. AU - Yerushalmi, R. AU - Woods, R. AU - Cheang, M. C. AU - Voduc, D. AU - Speers, C. H. PY - 2010 DA - 2010// TI - Metastatic behavior of breast cancer subtypes JO - J clin oncol: off j Am Soc Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.9820 DO - 10.1200/JCO.2009.25.9820 ID - Kennecke2010 ER - TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66544-0 DO - 10.1016/S0140-6736(05)66544-0 ID - ref5 ER - TY - JOUR AU - Berkowitz, N. AU - Gupta, S. AU - Silberman, G. PY - 2000 DA - 2000// TI - Estimates of the lifetime direct costs of treatment for metastatic breast cancer JO - Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research VL - 3 UR - https://doi.org/10.1046/j.1524-4733.2000.31003.x DO - 10.1046/j.1524-4733.2000.31003.x ID - Berkowitz2000 ER - TY - JOUR AU - Legorreta, A. P. AU - Brooks, R. J. AU - Leibowitz, A. N. AU - Solin, L. J. PY - 1996 DA - 1996// TI - Cost of breast cancer treatment. A 4-year longitudinal study JO - Arch Intern Med VL - 156 UR - https://doi.org/10.1001/archinte.1996.00440180055007 DO - 10.1001/archinte.1996.00440180055007 ID - Legorreta1996 ER - TY - JOUR AU - Taplin, S. H. AU - Barlow, W. AU - Urban, N. AU - Mandelson, M. T. AU - Timlin, D. J. AU - Ichikawa, L. PY - 1995 DA - 1995// TI - Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care JO - J Natl Cancer Inst VL - 87 UR - https://doi.org/10.1093/jnci/87.6.417 DO - 10.1093/jnci/87.6.417 ID - Taplin1995 ER - TY - JOUR AU - Rao, S. AU - Kubisiak, J. AU - Gilden, D. PY - 2004 DA - 2004// TI - Cost of illness associated with metastatic breast cancer JO - Breast Cancer Res Treat VL - 83 UR - https://doi.org/10.1023/B:BREA.0000010689.55559.06 DO - 10.1023/B:BREA.0000010689.55559.06 ID - Rao2004 ER - TY - STD TI - Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011;11:250–0. ID - ref10 ER - TY - JOUR AU - Wan, Y. AU - Gao, X. AU - Mehta, S. AU - Wang, Z. AU - Faria, C. AU - Schwartzberg, L. PY - 2013 DA - 2013// TI - Indirect costs associated with metastatic breast cancer JO - J Med Econ VL - 16 UR - https://doi.org/10.3111/13696998.2013.826228 DO - 10.3111/13696998.2013.826228 ID - Wan2013 ER - TY - STD TI - National Cancer Institute: Breast Cancer Treatment: Stage IV, Recurrent, and Metastatic Breast Cancer [http://www.cancer.gov/types/breast/hp/breast-treatment-pdq#link/_297_toc] 10/9/2013 UR - http://www.cancer.gov/types/breast/hp/breast-treatment-pdq#link/_297_toc ID - ref12 ER - TY - STD TI - Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, et al.: Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. 2014;21(6):703–14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13. ID - ref13 ER - TY - JOUR AU - Dodwell, D. AU - Wardley, A. AU - Johnston, S. PY - 2006 DA - 2006// TI - Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors JO - Breast (Edinburgh, Scotland) VL - 15 UR - https://doi.org/10.1016/j.breast.2006.01.007 DO - 10.1016/j.breast.2006.01.007 ID - Dodwell2006 ER - TY - STD TI - National Institute for Health and Care Excellence: Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptorpositive breast cancer after endocrine therapy. NICE technology appraisal guidance 295; 2013. https://www.nice.org.uk/guidance/ta295/resources/guidance-everolimus-in-combination-withexemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy-pdf. UR - https://www.nice.org.uk/guidance/ta295/resources/guidance-everolimus-in-combination-withexemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy-pdf ID - ref15 ER - TY - JOUR AU - Baselga, J. AU - Campone, M. AU - Piccart, M. AU - Burris, H. A. AU - Rugo, H. S. AU - Sahmoud, T. PY - 2012 DA - 2012// TI - Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer JO - N Eng J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1109653 DO - 10.1056/NEJMoa1109653 ID - Baselga2012 ER - TY - JOUR AU - Yardley, D. A. AU - Noguchi, S. AU - Pritchard, K. I. AU - Burris, H. A. AU - Baselga, J. AU - Gnant, M. PY - 2013 DA - 2013// TI - Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis JO - Adv Ther VL - 30 UR - https://doi.org/10.1007/s12325-013-0060-1 DO - 10.1007/s12325-013-0060-1 ID - Yardley2013 ER - TY - JOUR AU - Wilcken, N. AU - Dear, R. PY - 2008 DA - 2008// TI - Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007 JO - European journal of cancer (Oxford, England : 1990) VL - 44 UR - https://doi.org/10.1016/j.ejca.2008.07.019 DO - 10.1016/j.ejca.2008.07.019 ID - Wilcken2008 ER - TY - JOUR AU - Seidman, A. D. AU - Berry, D. AU - Cirrincione, C. AU - Harris, L. AU - Muss, H. AU - Marcom, P. K. PY - 2008 DA - 2008// TI - Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 JO - J clin oncol : off j Am Soc Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.11.6699 DO - 10.1200/JCO.2007.11.6699 ID - Seidman2008 ER - TY - JOUR AU - Gonzalez-Angulo, A. M. AU - Hortobagyi, G. N. PY - 2008 DA - 2008// TI - Optimal schedule of paclitaxel: weekly is better JO - J clin oncol : off j Am Soc Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.7651 DO - 10.1200/JCO.2007.15.7651 ID - Gonzalez-Angulo2008 ER - TY - JOUR AU - Blum, J. L. AU - Jones, S. E. AU - Buzdar, A. U. AU - LoRusso, P. M. AU - Kuter, I. AU - Vogel, C. PY - 1999 DA - 1999// TI - Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer JO - J clin oncol : off j Am Soc Clin Oncol VL - 17 ID - Blum1999 ER - TY - JOUR AU - Blum, J. L. AU - Dieras, V. AU - Lo Russo, P. M. AU - Horton, J. AU - Rutman, O. AU - Buzdar, A. PY - 2001 DA - 2001// TI - Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients JO - Cancer VL - 92 UR - https://doi.org/3.0.CO;2-A DO - 3.0.CO;2-A ID - Blum2001 ER - TY - JOUR AU - Venturini, M. AU - Paridaens, R. AU - Rossner, D. AU - Vaslamatzis, M. M. AU - Nortier, J. W. AU - Salzberg, M. PY - 2007 DA - 2007// TI - An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer JO - Oncology VL - 72 UR - https://doi.org/10.1159/000111094 DO - 10.1159/000111094 ID - Venturini2007 ER - TY - JOUR AU - Miller, K. AU - Wang, M. AU - Gralow, J. AU - Dickler, M. AU - Cobleigh, M. AU - Perez, E. A. PY - 2007 DA - 2007// TI - Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer JO - N Eng J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa072113 DO - 10.1056/NEJMoa072113 ID - Miller2007 ER - TY - JOUR AU - Robert, N. J. AU - Dieras, V. AU - Glaspy, J. AU - Brufsky, A. M. AU - Bondarenko, I. AU - Lipatov, O. N. PY - 2011 DA - 2011// TI - RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer JO - J clin oncol : off j Am Soc Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.28.0982 DO - 10.1200/JCO.2010.28.0982 ID - Robert2011 ER - TY - JOUR AU - Lloyd, A. AU - Nafees, B. AU - Narewska, J. AU - Dewilde, S. AU - Watkins, J. PY - 2006 DA - 2006// TI - Health state utilities for metastatic breast cancer JO - Br J Cancer VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603326 DO - 10.1038/sj.bjc.6603326 ID - Lloyd2006 ER - TY - STD TI - WHO: Choosing interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds [http://www.who.int/choice/costs/CER_thresholds/en/index.html] UR - http://www.who.int/choice/costs/CER_thresholds/en/index.html ID - ref27 ER - TY - STD TI - International Monetary Fund: World Economic Outlook Database [http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx] UR - http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx ID - ref28 ER -